LYNZI SWARTZ: Open Payments
NPI 1336786342 · NEW YORK, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,046 in 79 payments from 9 companies in 2025. Trend: 2023 $542 · 2024 $991 · 2025 $2,046
Food & beverage: $1,992Education: $54
| Company | Payments | Amount |
|---|---|---|
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 47 | $685 |
| Janssen Biotech, Inc. | 8 | $551 |
| ABBVIE INC. | 17 | $436 |
| GENZYME CORPORATION | 1 | $124 |
| Lilly USA, LLC | 1 | $120 |
| VIVUS LLC | 2 | $44 |
| Ferring Pharmaceuticals Inc. | 1 | $41 |
| Janssen Scientific Affairs, LLC | 1 | $23 |
| Ardelyx, Inc. | 1 | $22 |
Products named: XIFAXAN, TREMFYA, SKYRIZI, DUPIXENT, OMVOH, LINZESS, RINVOQ, PANCREAZE.
Industry payments across NY — which companies pay providers there.
